 "Delhi High Court grants interim; restrains sale of Corex syrup")
The Delhi High Court today granted interim stay of notification restraining sale of pharma major Pfizer's cough syrup 'Corex' and directed the government not to take coercive steps against the company.
Justice Rajiv Sahai Endlaw granted the interim relief to the company saying it has been selling the cough syrup for the last 25 years.
The court also issued notice to the Health ministry directing it to file status report after taking instruction on what was the finding of the expert committee set up by it following which sale of over 300 drugs' combination have been banned across India with effect from March 10.
"List on Monday. Till then the effect of notification by the petitioner shall remain stayed. No coercive steps till then," the court said.
The court's order came on a plea moved by Pfizer who contended that no show cause notice or hearing was granted prior to the notification.
Justice Rajiv Sahai Endlaw granted the interim relief to the company saying it has been selling the cough syrup for the last 25 years.
Read more from our special coverage on "PFIZER"
The court also issued notice to the Health ministry directing it to file status report after taking instruction on what was the finding of the expert committee set up by it following which sale of over 300 drugs' combination have been banned across India with effect from March 10.
"List on Monday. Till then the effect of notification by the petitioner shall remain stayed. No coercive steps till then," the court said.
The court's order came on a plea moved by Pfizer who contended that no show cause notice or hearing was granted prior to the notification.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%